Rehan Khan Explores Clopidogrel
Rehan Khan, Hospital Pharmacist and Manager Auctus Hospital, shared on LinkedIn:
”Day 2/365 – Medicine of the Day: CLOPIDOGREL
One-Sentence Definition
Clopidogrel is an antiplatelet drug used to prevent blood clot formation in patients with cardiovascular and cerebrovascular diseases.
Pharmacological Overview
Drug class: Antiplatelet agent (P2Y₁₂ receptor inhibitor)
Drug type: Prodrug
Primary role: Prevention of arterial thrombosis
Therapeutic Uses
- Acute Coronary Syndrome (ACS)
- Post–myocardial infarction (MI)
- Stroke and TIA prevention
- After coronary stent placement
- Alternative in aspirin intolerance
Mechanism of Action (MOA)
- Inhibits ADP (P2Y₁₂) receptors on platelets
- Prevents activation of GPIIb/IIIa complex
- Lowers Platelet aggregation
- Effect lasts for platelet lifespan (7–10 days)
Common Dose
- Maintenance dose: 75 mg once daily
- Loading dose (ACS/PCI): 300–600 mg stat
Key Adverse Effects
Bleeding (most common)
Gastrointestinal upset
Rare: Thrombotic thrombocytopenic purpura (TTP)
Clinical Pearl
Clopidogrel is a prodrug—its efficacy depends on liver enzyme activation (CYP2C19).
HISTORY OF CLOPIDOGREL
1980s: Development of thienopyridine antiplatelets
1997: Clopidogrel approved for clinical use
CAPRIE trial: Showed superiority over aspirin in reducing ischemic events
Modern era: Backbone of dual antiplatelet therapy (DAPT) with aspirin
Why Clopidogrel Matters
- Essential in cardiology and interventional practice
- Life-saving in stent patients
- WHO essential cardiovascular medicine
Widely used globally in ACS protocols”
Stay updated with Hemostasis Today.
-
Jan 2, 2026, 12:53José Antonio García Erce: The National Transplant Organization Published the 2024 Report of the Global Observatory on Donation and Transplantation
-
Jan 2, 2026, 12:48Reza Shojaei: Stepping into 2026 – Your Daily Commitment Saves Lives
-
Jan 2, 2026, 09:36Shashank K R on The Use of Lumbrokinase from Eudrilus eugeniae
-
Jan 2, 2026, 09:06Gokhan Ozdemir on Thrombophilia in Young Ischemic Stroke
-
Jan 2, 2026, 08:47Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
-
Jan 2, 2026, 03:52Abdul Mannan: When Gender Bias Becomes a Diagnostic Error – Inherited Bleeding Disorders are Still Being Missed
-
Jan 2, 2026, 03:51Samwel Mikaye: Thrombocytopenia in Pregnancy
-
Jan 2, 2026, 03:50Marc Carrier: Clinicians Working With Cancer Patients on DOACs. We Need Your Expertise!
-
Jan 2, 2026, 03:50Emicizumab in Infants: Not Just Cost-effective but Mandatory